Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 8,720 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Part A Clear all
Completed Not applicable Interventional Results available

The Influence of Default Options in Advance Directives

NCT01346176
View directory record Official record
Conditions
Advance Care Planning
Interventions
Advance Directive Forms
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 20, 2026, 5:09 AM EDT
Completed Not applicable Interventional

A Clinical Trial of Cognitive Multisensory Rehabilitation for Sensory and Motor Recovery in Adults With Spinal Cord Injury

NCT05167032
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Cognitive Multisensory Rehabilitation (CMR), Adaptive fitness
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 20, 2026, 5:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A 2 Part Study to Assess the Relative Bioavailability of Tablet Formulation Compared to Capsule Formulation and the Effect of Food and Taste Assessment on the Tablet Formulation in Healthy Participants

NCT03847987
View directory record Official record
Conditions
Healthy Volunteers
Interventions
RO7017773 Phase I Capsule, RO7017773 Phase II Tablet Unflavored, RO7017773 Phase II Tablet Sweetened/Flavored
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 20, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906

NCT05296733
View directory record Official record
Conditions
Healthy, Liver Diseases, Obesity
Interventions
BI 456906
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Chandler, Arizona • Fort Myers, Florida • Sarasota, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 20, 2026, 5:09 AM EDT
Recruiting Phase 1 Interventional

A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)

NCT07416552
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
SPLIT Abs, 203Pb-DOTAM, 212Pb-DOTAM
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
5
States / cities
Chicago, Illinois • St Louis, Missouri • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 5:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of the Construct Validity of Community Walking Speed Data Collected Remotely With the Canary canturioTM te Tibial Extension

NCT05539326
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Performance Clinical Outcome Test
Other
Lead sponsor
Canary Medical
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
6
States / cities
Frisco, Colorado • South Bend, Indiana • Jackson, Mississippi + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 20, 2026, 5:09 AM EDT
Completed Not applicable Interventional

Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates

NCT00037752
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Obesity
Interventions
Sibutramine, Behavioral Smoking Cessation Program
Drug · Behavioral
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 20, 2026, 5:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Identifying Body Awareness-related Brain Network Changes During Cognitive Multisensory Rehabilitation for Reduced Neuropathic Pain in People With Spinal Cord Injury

NCT04706208
View directory record Official record
Conditions
Spinal Cord Injuries, Neuropathic Pain
Interventions
Cognitive Multisensory Therapy, Usual Care, Clinical Assessment, Magnetic Resonance Imaging (MRI), OPTIONAL: blood draw
Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 5:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants

NCT04175925
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986322, BMS-986322 Placebo, famotidine
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 20, 2026, 5:09 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

NCT05378425
View directory record Official record
Conditions
Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor
Interventions
NTX-1088, Pembrolizumab
Drug
Lead sponsor
Nectin Therapeutics Ltd
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Duarte, California • New Orleans, Louisiana • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 20, 2026, 5:09 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT07306832
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Pivekimab Sunirine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Months to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Palo Alto, California • Atlanta, Georgia • Valhalla, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 5:09 AM EDT
Terminated Phase 1 Interventional

Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML

NCT05716009
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Dose Escalation -tagraxofusp-erzs, Dose Expansion at RP2D -tagraxofusp-erzs
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 20, 2026, 5:09 AM EDT
Completed Phase 4 Interventional

Rectus Sheath Block for Analgesia After Gynecological Laparotomy

NCT06575699
View directory record Official record
Conditions
Gynecologic Surgical Procedures
Interventions
Rectus sheath block, Thoracic Epidural Analgesia, Liposomal bupivacaine, Bupivacaine Hydrochloride, Bupivacaine-Hydromorphone Cassette
Procedure · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 20, 2026, 5:09 AM EDT
Not listed No phase listed Observational

A Detailed Look At What Patients Experience When They Take Part In Hypertension Clinical Trials

NCT05910255
View directory record Official record
Conditions
Hypertension
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 20, 2026, 5:09 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women

NCT03488108
View directory record Official record
Conditions
Alopecia
Interventions
Platelet Rich Plasma, Minoxidil Foam
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 20, 2026, 5:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)

NCT02324049
View directory record Official record
Conditions
Mucopolysaccharidosis IIIB
Interventions
SBC-103
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 12 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Minneapolis, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 20, 2026, 5:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin

NCT00423852
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Interventions
filgrastim, carboplatin, ifosfamide, paclitaxel, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 20, 2026, 5:09 AM EDT
Active, not recruiting Not applicable Interventional

Study of Posterior Cervical Stabilization System (PCSS) as Part of Circumferential Fusion to Treat Multilevel DDD

NCT04229017
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Anterior Cervical Discectomy and Fusion, Posterior Cervical Stabilization System (PCSS)
Procedure · Device
Lead sponsor
Providence Medical Technology, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
17
States / cities
Phoenix, Arizona • Encinitas, California • Los Gatos, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 20, 2026, 5:09 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease

NCT02850406
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Months to 17 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
13
States / cities
Brentwood, California • Washington D.C., District of Columbia • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 20, 2026, 5:09 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A

NCT05685238
View directory record Official record
Conditions
Haemophilia A, Haemophilia A With Inhibitors
Interventions
Mim8
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 20, 2026, 5:09 AM EDT
Recruiting Phase 1 Interventional

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

NCT07037758
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
Tarlatamab, AB248
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 90 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
13
States / cities
Gilbert, Arizona • Los Angeles, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients

NCT04501276
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumors
Interventions
ADG116, ADG106, anti PD1 drug
Drug
Lead sponsor
Adagene Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 20, 2026, 5:09 AM EDT
Recruiting Not applicable Interventional

Improving ADHD Teen Driving - Virtual Reality

NCT06960980
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
FOCAL+, VR-FOCAL+
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
16 Years to 19 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 20, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab

NCT02013154
View directory record Official record
Conditions
Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction, Gastroesophageal Cancer, Squamous Cell Carcinoma, Gastric Adenocarcinoma
Interventions
DKN-01 150 mg, Paclitaxel, Pembrolizumab, DKN-01 300 mg
Drug
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 20, 2026, 5:09 AM EDT